Structure Therapeutics (GPCR) Earnings Analysis

Structure Therapeutics (GPCR) next reports earnings on 2026-08-06, consensus EPS -0.39 USD. Last quarter (2026-05-07) it beat with EPS -0.35 USD vs -0.39 USD est (+10.3%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -19.09.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does GPCR next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.39 USD
Revenue estimaten/a

GPCR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.35 USD-0.39 USD+10.3%Beat
2026-02-26-0.49 USD-0.35 USD-40%Miss
2025-11-06-0.37 USD-0.36 USD-2.8%Miss
2025-02-27-0.22 USD-0.23 USD+4.3%Beat
2024-08-08-0.18 USD-0.23 USD+21.7%Beat

Beat rate: 3/5 (60%) over reported quarters with consensus data.

GPCR valuation and analyst view

Trailing P/E-19.09
Trailing EPS-2.35448 USD
Price / book2.52
Dividend yield0.00%
Market cap2.84B
Analyst consensusBuy (14 buy / 0 hold / 0 sell)
Avg price target85.5 USD

Related research pages

Frequently asked questions

When is Structure Therapeutics (GPCR)'s next earnings date?

Structure Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.39 USD.

Did GPCR beat earnings last quarter?

In its 2026-05-07 report, GPCR posted EPS of -0.35 USD versus a -0.39 USD estimate — a beat of 10.3%.

What is GPCR's earnings track record?

Over the last 5 reported quarters with consensus data, GPCR beat estimates 3 times (60%).

What is GPCR's current P/E ratio and EPS?

GPCR trades at a trailing P/E of -19.09 on trailing EPS of -2.354483821539991 USD.

What do analysts rate GPCR?

Analyst consensus is "Buy" across 14 ratings (0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 85.5 USD.